SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Vigil Neuroscience is a biotechnology business based in the US. Vigil Neuroscience shares (VIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Vigil Neuroscience employs 52 staff and has a market cap (total outstanding shares value) of 0.00.
SoFi Invest
eToro
Robinhood
Latest market close | $12.09 |
---|---|
52-week range | $2.18 - $18.27 |
50-day moving average | $11.66 |
200-day moving average | $8.35 |
Wall St. target price | $19.60 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-6.45 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.09 from 2023-02-07
1 week (2023-02-02) | 10.31% |
---|---|
1 month (2023-01-09) | 0.42% |
3 months (2022-11-09) | -1.87% |
6 months (2022-08-09) | 80.45% |
1 year (2022-02-09) | -16.56% |
---|---|
2 years (2021-02-05) | N/A |
3 years (2020-02-05) | N/A |
5 years (2018-02-05) | N/A |
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -41.5% |
Return on equity TTM | -77.81% |
Profit margin | 0% |
Book value | $5.79 |
Market capitalisation | $400.3 million |
TTM: trailing 12 months
We're not expecting Vigil Neuroscience to pay a dividend over the next 12 months.
You may also wish to consider:
Vigil Neuroscience, Inc. , a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It utilizes the tools of neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and families. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.